Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

hMSC

Phase 2Biologic

SStemedica Cell Technologies, Inc.

hMSC is one of 3 biologic programs targeting Mesenchymal Stem Cells. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

2

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mesenchymal Stem CellsRecruiting

Mesenchymal Stem CellsPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Mesenchymal Stem Cells

#DrugCompanyPhaseTrials

Allorx

TThe Foundation for Orthopaedics and Regenerative Medicine

hMSC

SStemedica Cell Technologies, Inc.

Hexell-2020

HHexun Biosciences Co., LTD.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mesenchymal Stem Cells1 trial

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

Recruiting·BBernard (Barry) Baumel·Phase 2·NCT06781333·8 enrolled

COVID-191 trial

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Unknown status·SStemedica Cell Technologies, Inc.·Phase 2·NCT04780685·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for hMSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hMSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hMSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stemedica Cell Technologies, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SStemedica Cell Technologies, Inc.

Related News